Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4997567 | 0.78 | TAAR1 (0.43) | TAAR1LMNAAKR1B1MEN1KMT2A | |
| SCHEMBL1182380 | 0.73 | MPO (0.42) | TAAR1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18462099 | 0.71 | TAAR1 (0.58) | TAAR1LMNAAKR1B1KMT2ASMN1; SMN2 | |
| SCHEMBL3333154 | 0.71 | TAAR1 (0.55) | TAAR1LMNAAKR1B1KMT2ASMN1; SMN2 | |
| SCHEMBL229621 | 0.69 | BCL2 (0.48) | MEN1KMT2ATSHRGAAL3MBTL1 | |
| SCHEMBL229340 | 0.68 | BCL2 (0.47) | MEN1KMT2ATSHRGAAL3MBTL1 | |
| SCHEMBL27531248 | 0.68 | TAAR1 (0.42) | TAAR1LMNAAKR1B1MEN1KMT2A | |
| SCHEMBL2116159 | 0.67 | ADRA2A (0.45) | TAAR1LMNAMAPT | |
| SCHEMBL12597084 | 0.66 | TAAR1 (0.44) | TAAR1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6141246 | 0.66 | TAAR1 (0.50) | TAAR1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026248-B2 | 4-[[4-[(2,6-dichloro-phenyl)methyl]-6-[[2-(1-pyrrolidinyl)ethyl]amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzamide, N1-oxide combined with another retrovirus inhibitor; viricides; treatment of AIDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-09-27 | — | — | US | disclosed |
| EP-1245567-B1 | HIV inhibiting pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-02 | — | — | EP | disclosed |
| US-7887845-B2 | Particle of a solid dispersion composed of a water soluble polymer and etravirine or salt thereof; etravirine FDA Orange book listed patent | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-15 | — | — | US | disclosed |
| US-20100172970-A1 | ANTIVIRAL COMPOSITIONS | VERRECK GEERT | 2010-07-08 | — | — | US | disclosed |
| US-20070196478-A1 | ANTIVIRAL COMPOSITIONS | VERRECK GEERT | 2007-08-23 | — | — | US | disclosed |
| US-7241458-B1 | Antiviral compositions | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | disclosed |
| US-20060127487-A1 | Antiviral compositions | VERRECK GEERT | 2006-06-15 | — | — | US | disclosed |
| EP-1225874-B1 | ANTIVIRAL SOLID DISPERSIONS | JANSSEN PHARMACEUTICA NV (BE) | 2006-02-01 | — | — | EP | disclosed |
| US-20050197354-A1 | 4-[[4-[(2,6-dichloro-phenyl)methyl]-6-[[2-(1-pyrrolidinyl)ethyl]amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzamide, N1-oxide combined with another retrovirus inhibitor; viricides; treatment of AIDS | ANDRIES KOENRAAD JOZEF L M (BE) | 2005-09-08 | — | — | US | disclosed |
| US-20050192305-A1 | HIV inhibiting pyrimidine derivatives | ANDRIES KOENRAAD JOZEF L M (BE) | 2005-09-01 | — | — | US | disclosed |
| EP-0945443-B1 | HIV inhibiting pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2003-02-12 | — | — | EP | disclosed |
| EP-1245567-A1 | HIV inhibiting pyrimidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-10-02 | — | — | EP | disclosed |
| US-6440986-B2 | VIRICIDES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2002-08-27 | — | — | US | disclosed |
| EP-1225874-A1 | ANTIVIRAL COMPOSITIONS | Janssen Pharmaceutica N.V. (BE) | 2002-07-31 | — | — | EP | disclosed |
| US-20010011094-A1 | HIV inhibiting pyrimidine derivatives | ANDRIES KOENRAAD JOZEF LODEWIJ (BE) | 2001-08-02 | — | — | US | disclosed |
| WO-2001022938-A1 | ANTIVIRAL COMPOSITIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-04-05 | — | — | WO | disclosed |
| US-6197779-B1 | VIRICIDE | JANSSEN PHARMACEUTICA, INC. | 2001-03-06 | — | — | US | disclosed |
| WO-1999050250-A1 | HIV INHIBITING PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-10-07 | — | — | WO | disclosed |
| EP-0945442-A1 | Trisubstituted pyrimidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-09-29 | — | — | EP | disclosed |
| EP-0945443-A1 | HIV inhibiting pyrimidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196478-A1 | ANTIVIRAL COMPOSITIONS | EIF2AK2, ZC3HAV1, RPL35 | TAAR1 4790/4885LMNA 2758/4885AKR1B1 3435/4885 |
| US-20050192305-A1 | HIV inhibiting pyrimidine derivatives | NR4A1, CCR5, NR4A3 | TAAR1 222/4885LMNA 3546/4885AKR1B1 142/4885 |
| US-20010011094-A1 | HIV inhibiting pyrimidine derivatives | CBR1, CCR1, NR4A1 | TAAR1 208/4885LMNA 2870/4885AKR1B1 337/4885 |
| US-20050197354-A1 | 4-[[4-[(2,6-dichloro-phenyl)methyl]-6-[[2-(1-pyrrolidinyl)ethyl]amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzamide, N1-oxide combined with another retrovirus inhibitor; viricides; treatment of AIDS | HAVCR2, CBR1, NR4A1 | TAAR1 159/4885LMNA 2854/4885AKR1B1 193/4885 |
| US-20100172970-A1 | ANTIVIRAL COMPOSITIONS | EIF2AK2, ZC3HAV1, RPL35 | TAAR1 4790/4885LMNA 2758/4885AKR1B1 3435/4885 |
| US-20060127487-A1 | Antiviral compositions | EIF2AK2, ZC3HAV1, RPL35 | TAAR1 4790/4885LMNA 2758/4885AKR1B1 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.